BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37543629)

  • 21. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.
    Christiansen Arlien-Søborg M; Trolle C; Alvarson E; Bæk A; Dal J; Otto Lunde Jørgensen J
    Endocrine; 2017 Jun; 56(3):589-594. PubMed ID: 28260207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone.
    Subbarayan SK; Fleseriu M; Gordon MB; Brzana JA; Kennedy L; Faiman C; Hatipoglu BA; Prayson RA; Delashaw JB; Weil RJ; Hamrahian AH
    Endocr Pract; 2012; 18(6):817-25. PubMed ID: 22784832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
    Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
    Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and management of acromegaly: giant invasive adenoma.
    Cahyanur R; Setyawan W; Sudrajat DG; Setyowati S; Purnamasari D; Soewondo P
    Acta Med Indones; 2011 Apr; 43(2):122-8. PubMed ID: 21785175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.
    Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Bruce JN
    Pituitary; 2003; 6(4):175-80. PubMed ID: 15237928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of acromegaly in a patient with type 1 diabetes mellitus.
    Hofmann EA; Polonsky KS; Weiss RE
    Endocr Pract; 2002; 8(2):113-8. PubMed ID: 11942776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
    Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
    PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Discrepancy between IGF-1 and GH during 75 g oral glucose tolerance test measures to acromegaly screening in a patient with macroprolactinoma--case report and literature review].
    Gonçalves FT; Feibelmann TC; Fernandes ML; Fonseca AR; Arantes HP; Jorge PT
    Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):494-9. PubMed ID: 17546251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature.
    Minniti G; Jaffrain-Rea ML; Esposito V; Santoro A; Tamburrano G; Cantore G
    Endocr Relat Cancer; 2003 Dec; 10(4):611-9. PubMed ID: 14713271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
    Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
    Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
    Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
    Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
    Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
    Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
    J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.
    De P; Rees DA; Davies N; John R; Neal J; Mills RG; Vafidis J; Davies JS; Scanlon MF
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3567-72. PubMed ID: 12915637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
    Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly.
    Freda PU; Bruce JN; Reyes-Vidal C; Singh S; DeLeon Y; Jin Z; Khandji AG; Cremers S; Post KD
    Pituitary; 2021 Apr; 24(2):170-183. PubMed ID: 33124000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.